<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01244009</url>
  </required_header>
  <id_info>
    <org_study_id>MK-4827-002</org_study_id>
    <nct_id>NCT01244009</nct_id>
  </id_info>
  <brief_title>A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)</brief_title>
  <official_title>A Phase II Efficacy Study of MK-4827 in Patients With Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tesaro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tesaro, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the efficacy and safety of MK-4827 in participants with relapsed&#xD;
      mantle cell lymphoma (MCL) and in a subset of participants with inactivation of the&#xD;
      Ataxia-Telangiectasia Mutated (ATM) gene.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor decision&#xD;
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">August 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who have a complete response (CR) or partial response (PR) during the study</measure>
    <time_frame>Tumor assessments will be performed every 9 weeks for the first year the participant is on treatment, every 12 weeks in year 2, and every 6 months in year 3 and beyond</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with adverse events</measure>
    <time_frame>From the day of enrollment through 30 days after the last dose of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from allocation to disease progression or death from any cause (Progression-free survival)</measure>
    <time_frame>Tumor assessments will be performed every 9 weeks for the first year the participant is on treatment, every 12 weeks in year 2, and every 6 months in year 3 and beyond</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Lymphoma</condition>
  <condition>Mantle-Cell</condition>
  <arm_group>
    <arm_group_label>MK-4827</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All Participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-4827</intervention_name>
    <description>MK-4827 will be administered daily as an oral formulation in continuous 21-day cycles.</description>
    <arm_group_label>MK-4827</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria :&#xD;
&#xD;
          -  Participant must have a diagnosis of MCL that has relapsed after at least one prior&#xD;
             chemotherapy regimen or for which the participant has refused standard therapy&#xD;
&#xD;
          -  Participant has measureable disease defined by lymphadenopathy, organomegaly, bone&#xD;
             marrow involvement and/or circulating lymphoma cells. At least one lesion must be &gt; 2&#xD;
             cm in the longest diameter and measurable in 2 perpendicular dimensions&#xD;
&#xD;
          -  Participant has a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology&#xD;
             Group (ECOG) Performance Scale&#xD;
&#xD;
          -  Female participants of child-bearing potential agree to use two approved contraceptive&#xD;
             methods or remain abstinent throughout the study&#xD;
&#xD;
          -  Male participants agree to use an adequate method of contraception throughout the&#xD;
             study&#xD;
&#xD;
          -  Participant has no history of prior cancer except certain cervical, skin, or prostate&#xD;
             cancers, or has undergone potentially curative therapy with no recurrence for five&#xD;
             years, or is deemed at low risk for recurrence&#xD;
&#xD;
          -  Participant has not had any platelet or red blood cell transfusions or colony&#xD;
             stimulating factor support during the month prior to treatment&#xD;
&#xD;
          -  Participant has a pre-study diagnostic formalin fixed paraffin-embedded tumor tissue&#xD;
             sample available&#xD;
&#xD;
        Exclusion Criteria :&#xD;
&#xD;
          -  Participant has had chemotherapy, radiotherapy, or biological therapy within 4 weeks&#xD;
             of screening&#xD;
&#xD;
          -  Participant has a history of central nervous system (CNS) lymphoma&#xD;
&#xD;
          -  Participant requires the use of corticosteroids&#xD;
&#xD;
          -  Participant is pregnant, breastfeeding, or expecting to conceive or father children&#xD;
             during the study&#xD;
&#xD;
          -  Participant is known to be human immunodeficiency virus (HIV)-positive&#xD;
&#xD;
          -  Participant has a history of Hepatitis B or C&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2016</verification_date>
  <study_first_submitted>November 17, 2010</study_first_submitted>
  <study_first_submitted_qc>November 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2010</study_first_posted>
  <last_update_submitted>November 3, 2016</last_update_submitted>
  <last_update_submitted_qc>November 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2016</last_update_posted>
  <responsible_party>
    <name_title>Vice President of Late Stage Development</name_title>
    <organization>Merck Sharp &amp; Dohme Corp</organization>
  </responsible_party>
  <keyword>Poly (ADP-ribose) polymerase (PARP) inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niraparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

